XML 40 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity Incentive Awards
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Equity Incentive Awards Equity Incentive Awards
Grants Issued Under the 2014 Plan
Our 2014 Equity Incentive Plan (the “2014 Plan”) was adopted by the Board of Directors on March 11, 2014 and approved by our stockholders on May 13, 2014.
During the quarter ended March 31, 2024, 90,378 shares of restricted stock were awarded to certain members of our management team. Of these shares, 50% are time-based awards, vesting in equal installments over a three-year period on February 4, 2025, February 3, 2026 and February 2, 2027, respectively, and have a grant date fair value of $3.0 million. The remaining 50% are performance-based awards vesting in equal installments on February 4, 2025, February 3, 2026 and February 7, 2027, respectively, upon meeting performance conditions as established by the Compensation Committee in the year of the vesting period. They are valued using the closing price at the grant date when all the key terms and conditions are
known to all parties. The 15,062 shares of restricted stock subject to 2024 performance goals have a grant date fair value of $1.0 million.
Grants Issued Under the 2024 Plan
Our 2024 Equity Incentive Plan (the “2024 Plan”) was adopted by our Board of Directors on February 6, 2024 and approved by our stockholders on April 30, 2024. The 2024 Plan replaces the 2014 Plan and is the sole plan available to us to provide equity incentive compensation to eligible participants as of its adoption. No further awards will be granted under the 2014 Plan. The 2024 Plan authorizes grants of options, restricted stock, and other forms of equity-based compensation, subject to conditions and restrictions determined by the Compensation Committee. Our Compensation Committee (or our Board of Directors with respect to awards made to our independent directors) determines the terms and conditions of each award at the time of grant, including whether payment of awards may be subject to the achievement of performance goals, consistent with the provisions of the 2024 Plan. A maximum of 3,766,336 shares of common stock are available for grant under the 2024 Plan.
During the quarter ended June 30, 2024, we awarded to certain members of our Board of Directors 16,626 shares of restricted stock at a fair value of approximately $1.0 million and options to purchase 29,855 shares of common stock with an exercise price of $60.29. These are time-based awards subject to various vesting dates between November 1, 2024 and April 30, 2027.
As of December 31, 2024, 3,759,490 shares remained available for future grants.
Restricted stock and options under the 2024 Plan have a maximum contractual term of ten years from the date of grant and have an exercise price not less than the fair value of the stock on the grant date. Individual grants could have different vesting periods but generally no longer than three and a half years. All restricted stock awards have non-forfeitable rights to dividend payments even if the underlying stock does not entirely vest.
Stock-based compensation expense, reported in General and administrative expense on the Consolidated Statements of Income and Comprehensive Income, for the years ended December 31, 2024, 2023 and 2022 was $6.7 million, $14.7 million and $10.5 million, respectively. Stock-based compensation expense of $14.7 million for the year ended December 31, 2023 includes accelerated vesting of stock-based compensation expense of $6.3 million recognized during the quarter ended June 30, 2023, as a result of the passing of a member of our Board of Directors.
Restricted Stock
A summary of our restricted stock activities and related information, is as follows:
Number of SharesWeighted Average Grant Date Fair Value Per Share
Balance at December 31, 2021314,907 $53.98
Shares granted130,600 $77.47
Shares forfeited/cancelled(11,881)$33.35
Shares vested(167,244)$48.99
Balance at December 31, 2022266,382 $69.24
Shares granted143,275 $56.63
Shares forfeited/cancelled— $—
Shares vested(228,478)$72.25
Balance at December 31, 2023181,179 $55.84
Granted107,004 $66.00
Forfeited/Cancelled(9,780)$69.95
Vested(99,462)$70.11
Balance at December 31, 2024178,941 $69.51

Compensation expense to be recognized subsequent to December 31, 2024, for restricted stock granted during or prior to 2024 that have not yet vested was $3.5 million, which is expected to be recognized over a weighted average term of 1.6 years.
Stock Options
The fair value of stock options granted was estimated on the grant date using the Black-Scholes-Merton model. The following table includes the assumptions made in the valuation:
20242023
Dividend Yield3.1%2.6%
Risk-Free Interest Rate4.6%3.4%
Expected Life5.8 years5.6 years
Expected Volatility28.7%28.1%
Weighted Average Grant Date Fair Value Per Share$15.28$16.31
There were 29,855 stock options granted during year ended December 31, 2024. No options were forfeited or expired for the years ended December 31, 2024, 2023 and 2022. A summary of our stock option activity and related information, is as follows:
Shares Subject To OptionsWeighted Average
Exercise Price Per Share		Weighted Average Outstanding Contractual Life (in years)Average Intrinsic Value (in millions)
Balance at December 31, 202173,775 $52.526.9$2.6
Options issued7,210 $79.72
Balance at December 31, 202280,985 $54.946.2$1.0
Options issued8,450 $68.01
Balance at December 31, 202389,435 $56.185.6$1.4
Options issued29,855 $60.29
Balance at December 31, 2024119,290 $57.215.8$1.3
Exercisable at December 31, 202490,993 $56.044.7$1.1